

## NEWSLETTER

### CHEMICAL & PHARMACEUTICAL

6 - 12 April 2026



#### **BASF opens sustainable Zhanjiang site**

Chemical giant BASF celebrated the official inauguration of its newly built, world-scale Verbund site in Zhanjiang, a coastal city in Guangdong province. Covering an area of around 4 square kilometers with an investment of around 8.7 billion euros (\$10 billion), it is more than a major BASF project in the chemical growth market of China. **(China Daily)**

#### **Ningxia Chemicals sets sights on expansion**

Ningxia Jiafeng Chemicals Co Ltd is rapidly consolidating its position in the global supply chain for a key diabetes drug ingredient, and the company anticipates a public listing. The company now accounts for about half of China's metformin hydrochloride production and more than 30% of global supply — a scale that underscores China's growing leverage in essential pharmaceutical inputs. **(China Daily)**

#### **World's Largest Single Coal-to-Ethylene Glycol Project Commences Construction**

The first phase of the Turpan City's 100 billion yuan-level coal-chemical-textile new materials integrated project — a 2.4 million tons/year high-quality fiber-grade coal-to-ethylene glycol project — officially commenced construction in the Turpan Economic Development Zone's Coal-Based New Materials Circular Industrial Park. **(ChemNet Chemical Headlines)**

#### **Chinese researchers design microrobot for precise particle, cell delivery**

Chinese researchers have created a 3D hand-shaped microrobot, smaller than a human hair, for precise particle and cell delivery. It features a pH-responsive "palm" for grasping objects and a magnetic module for guided transportation. Controlled by magnetic fields and pH changes, it can navigate obstacles, capture targets, and release them at specific locations. **(Xinhua)**

#### **China's pharmaceutical sector marks a 'breakthrough era'**

A new industry report declares China's pharmaceutical sector has entered a "breakthrough era," transitioning from a generic-dominated market to one where innovative, homegrown drugs now hold over 30% market share in key hospitals. This shift was driven by pivotal policy reforms that streamlined approvals and improved patient affordability. As commercialization evolves, the focus is now on creating clinical value. **(China Daily)**